Charles River Laboratories International, Inc. provided earnings guidance for the full year of 2022. For the year, the company expects revenue growth in the range of 13.0% to 15.0% and GAAP EPS estimate in the range of $9.20 $9.45.
Charles River Laboratories International, Inc.
Equities
CRL
US1598641074
Biotechnology & Medical Research
Real-time Estimate
Other stock markets
|
5-day change | 1st Jan Change | ||
231 USD | -0.73% | +1.36% | -2.33% |
EPS Revisions
1st Jan change | Capi. | |
---|---|---|
-2.33% | 11.95B | |
+28.36% | 42.68B | |
-2.96% | 42.4B | |
+45.32% | 40.04B | |
-6.20% | 28.31B | |
+7.37% | 24.94B | |
-20.81% | 18.96B | |
+28.71% | 12.3B | |
-1.13% | 11.55B | |
+17.80% | 11.32B |
- Stock Market
- Equities
- CRL Stock
- News Charles River Laboratories International, Inc.
- Charles River Laboratories International, Inc. Provides Earnings Guidance for the Full Year of 2022